Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
IR

OTC · IRME

IR-Med Inc.

Healthcare · Medical - Devices

$0.00

Up+$0.00 (+0.00%)

Updated Sep 20, 2026, 7:12 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.32M
P/E ratio
-0.94
Dividend yield
0.00%
52-week range
— – —
Volume
594
Avg. volume
17.77K

Price performance

IRME price history

1M range · 0 trading sessions · Daily adjusted prices

IRME does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest IRME news

The latest Smart Investors Daily articles mentioning IRME.

Stock researchCompany · Overview

IRME research

Overview

Company profile and research snapshot.

Company profile

IR-MED INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 16, 2026

IR-MED and Dice Technologies Announce collaboration to Evaluate and Advance Pressure-Injury Prevention Platform in Japan

ROSH PINNA, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Letter of Intent (“LOI”) signed to cooperate in the evaluation, research support, localization, commercialization preparation and regulatory preparation of the PressureSafe™ medical device in Japan.Collaboration addresses a significant potential market need in Japan, which includes more than 36 million people aged 65 and older and approximately 8,000 hospitals, 13,600 long-term care facilities, and 16,000+ home-visit nursing stations.Strateg

newsfilecorp.com · Nov 3, 2025

IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment

DiaSafe™ technology for non-invasive DFU risk assessment and early intervention* The DFU treatment market is estimated to be approximately$10 billion globally 1 Rosh Pina, Israel--(Newsfile Corp. - November 3, 2025) - IR-MED Ltd. (OTCQB: IRME) (the "Company" or "IR-Med"), a pioneer in artificial intelligence ("AI")-driven, non-invasive infrared spectrographic medical device developer, today announced that it has initiated the first-in-human clinical trial of its DiaSafe™ device – built on the proven "sensing the invisible" platform – specifically targeting DFUs.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By